[Avoiding mistakes in anti-VEGF intravitreal injection therapy].

4区 医学 Q3 Medicine Ophthalmologe Pub Date : 2022-03-01 Epub Date: 2022-01-14 DOI:10.1007/s00347-021-01553-8
Carsten Framme, Bernd Junker, Nicolas Feltgen, Hans Hoerauf, Nina-Antonia Striebe, Joachim Wachtlin, Ingo Volkmann
{"title":"[Avoiding mistakes in anti-VEGF intravitreal injection therapy].","authors":"Carsten Framme,&nbsp;Bernd Junker,&nbsp;Nicolas Feltgen,&nbsp;Hans Hoerauf,&nbsp;Nina-Antonia Striebe,&nbsp;Joachim Wachtlin,&nbsp;Ingo Volkmann","doi":"10.1007/s00347-021-01553-8","DOIUrl":null,"url":null,"abstract":"<p><p>Intravitreal injection (IVI) of drugs for treatment of various macular diseases is now one of the most frequently performed surgical procedures worldwide. As mostly chronic diseases are treated, the indications for treatment often mean a continuous treatment over years with a corresponding effort regarding spatial, personnel and financial resources. The diagnosis and indications for treatment are nowadays mainly made by spectral domain optical coherence tomography (SD-OCT). The ability to clinically assess and evaluate a fluorescence angiography is less practiced, although these are still a component of the indications for intravitreal injections. Therefore, it can happen that despite all diligence patients may receive anti-vascular endothelial growth factor (VEGF) treatment, sometimes permanently, based on a misinterpretation of the macular diagnosis or disease activity and these indications, once made, are rarely questioned or retracted. Therefore, the aim of this manuscript is to point out possible and typical misinterpretations in the indications or continuation of IVI treatment with anti-VEGF by means of case studies and to sensitize for differential diagnoses.</p>","PeriodicalId":54676,"journal":{"name":"Ophthalmologe","volume":" ","pages":"309-326"},"PeriodicalIF":0.0000,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmologe","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00347-021-01553-8","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/14 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 3

Abstract

Intravitreal injection (IVI) of drugs for treatment of various macular diseases is now one of the most frequently performed surgical procedures worldwide. As mostly chronic diseases are treated, the indications for treatment often mean a continuous treatment over years with a corresponding effort regarding spatial, personnel and financial resources. The diagnosis and indications for treatment are nowadays mainly made by spectral domain optical coherence tomography (SD-OCT). The ability to clinically assess and evaluate a fluorescence angiography is less practiced, although these are still a component of the indications for intravitreal injections. Therefore, it can happen that despite all diligence patients may receive anti-vascular endothelial growth factor (VEGF) treatment, sometimes permanently, based on a misinterpretation of the macular diagnosis or disease activity and these indications, once made, are rarely questioned or retracted. Therefore, the aim of this manuscript is to point out possible and typical misinterpretations in the indications or continuation of IVI treatment with anti-VEGF by means of case studies and to sensitize for differential diagnoses.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
【抗vegf玻璃体内注射治疗中的避免失误】。
玻璃体内注射(IVI)药物治疗各种黄斑疾病是目前世界范围内最常用的外科手术之一。由于治疗的大多是慢性病,治疗指征往往意味着多年的持续治疗,需要在空间、人员和财政资源方面作出相应的努力。目前主要通过光谱域光学相干断层扫描(SD-OCT)进行诊断和治疗。临床评估和评价荧光血管造影的能力较少实践,尽管这些仍然是玻璃体内注射指征的一个组成部分。因此,有可能发生的是,尽管所有的努力,患者可能接受抗血管内皮生长因子(VEGF)治疗,有时是永久性的,基于对黄斑诊断或疾病活动性的误解,这些指征一旦做出,很少被质疑或撤回。因此,本文的目的是指出可能的和典型的误解在适应症或继续IVI治疗抗vegf通过案例研究和敏感的鉴别诊断。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Ophthalmologe
Ophthalmologe 医学-眼科学
CiteScore
1.80
自引率
0.00%
发文量
95
审稿时长
4-8 weeks
期刊介绍: Der Ophthalmologe is an internationally recognized journal dealing with all aspects of ophthalmology. The journal serves both the scientific exchange and the continuing education of ophthalmologists. Freely submitted original papers allow the presentation of important clinical studies and serve scientific exchange. Case reports feature interesting cases and aim at optimizing diagnostic and therapeutic strategies. Comprehensive reviews on a specific topical issue focus on providing evidenced based information on diagnostics and therapy. Review articles under the rubric ''Continuing Medical Education'' present verified results of scientific research and their integration into daily practice.
期刊最新文献
Myelin Oligodendrocyte Glycoprotein Antibody-Mediated Optic Neuritis Following COVID-19 Vaccination. [Acute unilateral impaired vision after COVID vaccination]. [Epidemiology and treatment of retinopathy of prematurity. The Hannover data in the Retina.net ROP registry from 2001-2017]. [Displacement of a STARflo glaucoma drainage implant with accompanying complications]. [Complete visual recovery after Nd:YAG laser polishing of the anterior surface of the intraocular lens].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1